Globally, we stand at a critical juncture for cancer care. While we know more about cancer than ever before – with breakthrough advances in early detection, precision diagnosis, targeted treatment, and survivor support – we face an unprecedented challenge. Cancer rates are rising worldwide, yet most countries lack comprehensive strategies to prevent cancer and reduce its devastating impact on individuals, families, and societies. Despite promising innovations, investment in cancer care is failing to keep pace with the accelerating burden of cancer.
In response to this urgent challenge, AstraZeneca has led the development of the Transforming Cancer Care by 2040 white paper, in conjunction with a group of experts in the field of oncology.
Together, these resources take both short- and long-term perspectives to demonstrate the critical importance of cancer care transformation and identify key opportunities for action.
We call on all stakeholders to review the white paper and consider how you can use this to guide national efforts to drive changes in cancer care. For any questions or if you would like to submit a best practice example of an innovative approach to cancer control, please contact AstraZeneca.
White paper on transforming cancer care by 2040: A roadmap to equitable, innovative and sustainable solutions:
Overview: Provides a detailed overview of what transformed cancer care could look like by 2040, including strategic recommendations for future proofing cancer care
How to use: Use this to guide policy and advocacy efforts to drive transformative changes in cancer care
Read more
Transforming Cancer Care By 2040: Case Study Compendium
Overview: Provides real-world examples of innovative approaches to cancer control
How to use: Use this to seek practical insights from successful strategies to inform future cancer control efforts
Read moreTransforming Cancer Care By 2040: Factsheet
Overview: Provides a concise summary of the key data and statistics discussed in detail within the white paper
How to use: Use this for information on critical trends across cancer care to inform your engagements and initiatives
Read more
Transforming Cancer Care By 2040: Glossary
Overview: Provides definitions for key terms and concepts used throughout the white paper and related resources
How to use: Use this to help navigate the concepts and terminology central to the discussion on shaping the future of cancer control
Read moreAcknowledgements
The development of this report has been funded and led by AstraZeneca, with the support and consultation of an expert group in the field of oncology. The expert group provided input throughout the process, including guidance on the paper’s direction, content, and recommendations. AstraZeneca would like to thank the contributors for their insights, as without whom, this work would not have been possible. Some of these experts received honoraria for their time as per local regulations and have been listed below, in alphabetical order.
External contributors
Andrea Feigl , Founder and CEO, Health Finance Institute
Dr Cary Adams , Chief Executive Officer, Union for International Cancer Control
Ebba Hallersjö Hult , Co-Founder and Head, Vision Zero Cancer
Dr Gilberto Lopes , Professor of Clinical Medicine, Medical Director for International Programmes, Associate Director for Global Oncology, Chief, Division of Medical Oncology, Sylvester Comprehensive Cancer at the University of Miami
Dr Ian Walker , Executive Director of Policy Information and Communications, Cancer Research UK
Richard Vines , Chair and Founder of International Programmes, Rare Cancers Australia
Šarūnas Narbutas , Founding Partner at Minds, Co-Founder and Chairman at Youth Cancer Europe, Chief Advisor at Lithuanian Cancer Patient Coalition, CAB member and ex-Chairman at CML Advocates Network
Internal contributors
Dr Bob Li , Global Head of Medical Affairs, Oncology, AstraZeneca
Chris McPherson , Head of Global Oncology Policy & Advocacy, AstraZeneca
Dave Fredrickson , Executive Vice-President, Oncology Business, AstraZeneca
Felicia Flowitt , Director of Oncology Policy (Pan-Tumour), AstraZeneca
Shira Gerver , Vice President, Global Head of Oncology Corporate Affairs, AstraZeneca
Stefan Weber , Vice President Global Policy, Advocacy & Health Equity, AstraZeneca
Dr Sunil Verma , Senior Vice President, Global Head, Oncology Franchise, AstraZeneca
